Skip to main content

Intellia Therapeutics, Inc. insider trading

NTLANASDAQ
$12.26+0.14 (+1.16%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (-40.0%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
DateCategoryPersonRoleActionAmountChange in holding
Open market purchase
Open market sell
Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Unlock quarterly net flow

Key players

  • JMJohn M. LeonardPresident and CEO0.8603%of company
  • FEFred E. CohenDirector0.1546%of company
  • JBJames BastaEVP, General Counsel0.1119%of company
  • EJEdward J. Dulac IIIEVP, Chief Financial Officer0.1057%of company
  • WJWilliam J. ChaseDirector0.1027%of company
  • BCBirgit C. SchultesEVP, Chief Scientific Officer0.0983%of company
  • DLDavid LebwohlEVP, Chief Medical Officer0.0936%of company
  • ECEliana ClarkEVP, Chief Technical Officer0.067%of company
  • LSLaura Sepp-LorenzinoEVP, Chief Scientific Officer0.0552%of company
  • MPMichael P. DubeVP, Chief Accounting Officer0.0477%of company

AI Activity Analysis

Premium
Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto
CompanyInsider / roleActionΔOwnAvg priceAmount
NTLAJohn M. LeonardPresident and CEOOpen market sell$36.2K-0.2%$13.00$36.2KAug 21, 2026Aug 24, 2026
NTLAJohn M. LeonardPresident and CEOOpen market sell$251K-1.6%$12.60$251KAug 20, 2026Aug 24, 2026
NTLAEdward J. Dulac IIIEVP, Chief Financial OfficerOpen market sell$91.2K-5.2%$11.25$91.2KJul 22, 2026Jul 24, 2026
NTLAEdward J. Dulac IIIEVP, Chief Financial OfficerOpen market sell$84.2K-2.9%$18.00$84.2KJul 2, 2026Jul 6, 2026
NTLAMichael P. DubeVP, Chief Accounting OfficerOpen market sell$44.3K-3.8%$16.78$44.3KJul 1, 2026Jul 6, 2026
NTLAJames BastaEVP, General CounselOpen market sell$16.7K-0.8%$13.78$16.7KMar 2, 2026Mar 3, 2026
NTLAEliana ClarkEVP, Chief Technical OfficerOpen market sell$8.36K-0.6%$13.78$8.36KMar 2, 2026Mar 3, 2026
NTLAJohn M. LeonardPresident and CEOOpen market sell$314K-3.1%$9.21$314KJan 5, 2026Jan 7, 2026
NTLABirgit C. SchultesEVP, Chief Scientific OfficerOpen market sell$78.4K-8.0%$9.21$78.4KJan 5, 2026Jan 7, 2026
NTLAJames BastaEVP, General CounselOpen market sell$95.8K-9.3%$9.21$95.8KJan 5, 2026Jan 7, 2026
NTLAFred E. CohenDirectorOpen market purchase$1.4M+261.1%$9.35$1.4MJan 5, 2026Jan 7, 2026
NTLADavid LebwohlEVP, Chief Medical OfficerOpen market sell$110K-8.9%$9.21$110KJan 5, 2026Jan 7, 2026
NTLAEliana ClarkEVP, Chief Technical OfficerOpen market sell$87.6K-9.9%$9.21$87.6KJan 5, 2026Jan 7, 2026
NTLAEdward J. Dulac IIIEVP, Chief Financial OfficerOpen market sell$58.8K-6.0%$9.21$58.8KJan 5, 2026Jan 7, 2026
NTLAMichael P. DubeVP, Chief Accounting OfficerOpen market sell$27.5K-5.4%$9.21$27.5KJan 5, 2026Jan 7, 2026
End of history · 15 transactions
SpoorBase

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.